Results 51 to 60 of about 137,903 (371)

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

open access: yesNew England Journal of Medicine, 2009
BACKGROUND Eosinophilic inflammation, which may be a consequence of interleukin-5 action, is a characteristic feature of some forms of asthma. However, in three previous clinical trials involving patients with asthma, blockade of this cytokine did not ...
Parameswaran Nair   +7 more
semanticscholar   +1 more source

Prevalence of asthma and COPD and blood eosinophil count in a middle-aged Belgian population [PDF]

open access: yes, 2019
Various phenotypes exist in asthma and Chronic Obstructive Pulmonary Disease (COPD). These are important to identify in order to guide treatment decisions.
Brusselle, Guy   +4 more
core   +1 more source

Challenges in managing a multifactorial eosinophilic pneumonia: daptomycin vs strongyloidiasis case report

open access: yesBMC Infectious Diseases, 2022
Background Eosinophilia is defined as a blood eosinophil count > 500/mcL with etiology usually an allergic reaction or parasitic infection which can lead to serious organ damage.
Lynda G. J. Eckhardt   +2 more
doaj   +1 more source

Eosinophilia in Filariasis [PDF]

open access: yesThe American Journal of the Medical Sciences, 1902
n ...
openaire   +2 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

Peripheral blood eosinophilia in dogs: Prevalence and associated diseases

open access: yesVeterinary Medicine and Science, 2022
Background Canine eosinophilia has not been evaluated over the last two decades. As in human local differences, changes in the prevalence and associated diseases over time can be expected.
Abigail Guija‐de‐Arespacochaga   +3 more
doaj   +1 more source

Hematological Neoplasms with Eosinophilia

open access: yesCancers, 2023
Eosinophils in peripheral blood account for 0.3–5% of leukocytes, which is equivalent to 0.05–0.5 × 109/L. A count above 0.5 × 109/L is considered to indicate eosinophilia, while a count equal to or above 1.5 × 109/L is defined as hypereosinophilia. In bone marrow aspirate, eosinophilia is considered when eosinophils make up more than 6% of the total ...
Rosario M. Morales-Camacho   +4 more
openaire   +4 more sources

Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD

open access: yesInternational Journal of COPD, 2016
Introduction Sputum eosinophilia occurs in approximately one-third of stable chronic obstructive pulmonary disease (COPD) patients and can predict exacerbation risk and response to corticosteroid treatments. Sputum induction, however, requires expertise,
Netsanet A Negewo   +6 more
semanticscholar   +1 more source

Cysticercosis and taeniasis cases diagnosed at two referral medical institutions, Belgium, 1990 to 2015 [PDF]

open access: yes, 2019
Background: Few case reports on human infections with the beef tapeworm Taenia saginata and the pork tapeworm, Taenia solium, diagnosed in Belgium have been published, yet the grey literature suggests a higher number of cases.
Bottieau, Emmanuel   +6 more
core   +1 more source

Artificial Intelligence‐Driven Nanoarchitectonics for Smart Targeted Drug Delivery

open access: yesAdvanced Materials, EarlyView.
This perspective introduces an artificial intelligence (AI)‐driven nanoarchitectonics framework for targeted drug delivery, combining database‐guided nanocarrier design, machine learning (ML)‐assisted surface engineering with a designed targeting system, and in silico modeling for dynamic optimization.
Hayeon Bae   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy